NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis Meeting Abstract
| Authors: | O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; Duh, M. S.; Chen, H. |
| Abstract Title: | NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis |
| Meeting Title: | 40th International Society for Pharmaceutical Engineering (ISPE) Conference |
| Journal Title: | Pharmacoepidemiology and Drug Safety |
| Volume: | 33 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Aug 24-28 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 1053-8569 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2024-11-01 |
| Start Page: | 176 |
| Language: | English |
| ACCESSION: | WOS:001407925901101 |
| PROVIDER: | wos |
| PUBMED: | 39562004 |
| DOI: | 10.1002/pds.5891 |
| Notes: | Meeting Abstract: 442 -- Source: Wos |
